News for Longeveron Inc. (LGVN)

Operator: Good day, and welcome to the Longeveron 2024 and Full Year Financial Results Conference Call. At this time all participants are in a listen-only mode.

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Conference Call February 28, 2025 4:30 PM ETCompany ParticipantsDerek Cole - IR, Advisory SolutionsWa'el...

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-Bâ„¢ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orpha

**media[553860,553861]**

Longeveron Inc (LGVN) is set to release its Q4 2024 earnings on Feb 28, 2025. The consensus estimate for Q4 2024 revenue is $0.63 million, and the earnings are

**media[546622]**

**media[544182]**

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

Cellular therapy Lomecel-Bâ„¢ has been granted an International Non-proprietary Name (INN) of ”œlaromestrocel” on the INN List issued by the World Health Org

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Co

MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. ( LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies f

**media[540841]**

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

**media[481925]**

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Co

MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. ( LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies f

**media[481069]**

Longeveron, Inc. (NASDAQ:LGVN) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsDerek Cole - IR, Advisory SolutionsWa'el...

Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24)....